Single User
£4350
PDF
70 pages

Oesophageal Cancer Forecast in 18 Major Markets 2017-2027


Oesophageal Cancer is an uncontrolled growth of abnormal cells which forms in the lining of the oesophagus.

Epithelial tumours of the oesophagus are responsible for the majority of oesophageal cancers. The majority of oesophageal cancers can be subdivided into two main histological subtypes:

  • Adenocarcinomas (AC)
  • Squamous cell carcinomas (SCC)

This report provides the current incident population for Oesophageal Cancer across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Turkey, India, China, Japan, Argentina, Brazil, Mexico, Australia, Saudi Arabia and South Africa) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Oesophageal Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

There are several features associated with the development and progression of oesophageal cancer, these include:

  • Fistula formation to trachea, bronchi or mediastinum (can be either due to direct tumour progression or iatrogenic effects (e.g. radiation therapy))
  • Oesophageal perforation
  • Cachexia
  • GORD
  • Smoking
  • Nausea or vomiting
  • Coughing

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Oesophageal Cancer market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Oesophageal Cancer and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Oesophageal Cancers incident population.
  • Identify sub-populations within Oesophageal Cancer which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Oesophageal Cancer patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line incidence for Oesophageal Cancer
  • Features of Oesophageal Cancer patients
    • Features of Patients with Adenocarcinoma Oesophageal Cancer
    • Features of patients with SCC Oesophageal Cancer
    • Features of rectal cancer patients
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • TNM staging
  • WHO histological classification of oesophageal tumours
  • Incidence of Oesophageal Cancer, total (000s)
  • Incidence of Oesophageal Cancer, males (000s)
  • Incidence of Oesophageal Cancer, females (000s)
  • AJCC Stage, total (000s)
  • Lymph node spread and metastases, total (000s)
  • Oesophageal cancer patients by histopathology, total (000s)
  • Location of cancer in adenocarcinoma patients, total (000s)
  • Oesophageal cancer patients with familial AC, total (000s)
  • Adenocarcinoma oesophageal cancer patients with GORD, total (000s)
  • Adenocarcinoma oesophageal cancer patients with history of smoking, total (000s)
  • Location of cancer in SCC patients, total (000s)
  • SCC Oesophageal cancer patients with history of smoking, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • USA Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • Canada Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • Canada Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • France Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • France Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • Germany Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • Germany Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • Italy Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • Italy Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • Spain Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • Spain Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • UK Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • UK Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • Brazil Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • Brazil Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • Japan Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • Japan Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • India Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • India Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • China Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • China Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • Turkey Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • Turkey Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • Australia Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • Australia Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • Mexico Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • Mexico Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • Argentina Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • Argentina Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • Russia Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • Russia Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • Saudi Arabia Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • Saudi Arabia Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
  • South Africa Incidence of Oesophageal Cancer by 5-yr age cohort, males (000s)
  • South Africa Incidence of Oesophageal Cancer by 5-yr age cohort, females (000s)
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russian Federation, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States of America